Lowering LDL-C levels through interventions like PCSK9 inhibitors may increase the risk of developing diabetes and metabolic dysfunction. — Whalespan
Lowering LDL-C levels through interventions like PCSK9 inhibitors may increase the risk of developing diabetes and metabolic dysfunction.
⚠ High risk
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
✕NOTSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
“so messing around with pcsk9 in people who they they have this genetically like they're born like this actually leads to increased risk of diabetes and metabolic dysfunction which is highly problematic because it's saying you have an increased risk of developing the fires even though your cholesterol is lower”
Video
Conflict Watch
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.